10Y annualized return is
positive but below market average
at 3.8% per year
MRK has met or exceeded earnings expectations in
most
recent quarters (9/10)
Attractive PE Ratio
Strong Price-to-Sales Ratio
Moderate Price-to-Book Ratio
High EV to EBITDA Ratio
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Merck demonstrates a strong business quality with a robust product portfolio and a diverse pipeline, though it faces challenges in specific markets like China. Future prospects remain positive due to ongoing innovation and strong pipeline developments, despite some uncertainties related to GARDASIL and competitive pressures in oncology.
Analysis Date: February 4, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Merck & Co., Inc. is a healthcare company that makes medicines and vaccines for both people and animals. They create treatments for serious health issues like cancer, diabetes, and infections, and also produce vaccines to help prevent diseases. In addition, Merck develops products to keep animals healthy, including vaccines and medicines for pets and livestock. Founded in 1891, the company is based in New Jersey and works with other organizations to improve health solutions.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect MRK's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact MRK's performance.
Access Full Risk AnalysisLatest News
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights